Abstract
A 62-year-old woman with psoriasis and psoriatic arthritis presented for evaluation and treatment of a one-week history of pruritic, pink spots on her trunk and extremities. Several weeks prior, therapy with certolizumab pegol and methotrexate was started for her psoriatic arthritis. A biopsy specimen was consistent with the diagnosis of porokeratosis. Owing to the setting of immunosuppression and presence of symmetric pruritic lesions on non-sun exposed areas, the diagnosis of disseminated superficial porokeratosis was made.
MeSH terms
-
Antibodies, Monoclonal, Humanized
-
Arthritis, Psoriatic / drug therapy
-
Biopsy
-
C-Reactive Protein / metabolism
-
Certolizumab Pegol
-
Female
-
Humans
-
Immunoglobulin Fab Fragments / adverse effects*
-
Immunoglobulin Fab Fragments / therapeutic use
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
Methotrexate / adverse effects*
-
Methotrexate / therapeutic use
-
Middle Aged
-
Neutrophils
-
Polyethylene Glycols / adverse effects*
-
Polyethylene Glycols / therapeutic use
-
Porokeratosis / chemically induced*
-
Porokeratosis / diagnosis*
-
Porokeratosis / pathology
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin Fab Fragments
-
Immunosuppressive Agents
-
Polyethylene Glycols
-
C-Reactive Protein
-
Certolizumab Pegol
-
Methotrexate